Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 15, 2022
The current study tested the biomechanical strength of the newly regenerated esophageal tissue and demonstrated that the strength of the tissue was comparable to adjacent native tissue. HOLLISTON,...
-
May 16, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
May 13, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo...
-
May 10, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Apr 11, 2022
Extends Core Intellectual Property coverage for treatment of lung cancer as well as esophageal cancer. HOLLISTON, Mass., April 11, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or...
-
Apr 1, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Mar 30, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Jan 25, 2022Thursday, Jan. 27. 2-3pm ET via Zoom
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Jan 25, 2022Court holds that Biostage's insurer breached its duty to defend a litigation from the estate of a patient who died after being treated with a Biostage Tracheal Implant.
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Jan 10, 2022Establishes the basis for a clinical trial in human babies with birth defects in the esophagus.
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial...
-
Nov 30, 2021New CEO Invests $250,000 in Private Placement and is Appointed as Board Chairman
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial...
-
Nov 15, 2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today...
-
Sep 8, 2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing novel organ regeneration technology based its patented Cellframe™ and Cellspan™ technology,...
-
Aug 13, 2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today...
-
May 24, 2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today...
-
Apr 13, 2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing next-generation bioengineered esophageal implants, today announced its financial results for the...
-
Jan 25, 2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it appointed Herman Sanchez as an...
-
Nov 13, 2020
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspan™ technology for...
-
Aug 13, 2020
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspan™ technology for...
-
May 14, 2020
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspan™ technology,...
-
Mar 27, 2020- FDA Removes clinical hold on Cellspan™ Esophageal Implant (CEI) study
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing next-generation esophageal implants, today announced its financial results for the three and twelve...
-
Mar 20, 2020Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan™ Esophageal Implant
Biostage, Inc. (OTCQB: BSTG) (Biostage or the Company), a bioengineering company developing next-generation esophageal implants, today announced that the U.S. Food and Drug Administration (FDA)...
-
Feb 20, 2020
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it has submitted its official response to...
-
Jan 2, 2020
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, received the anticipated formal response from the U.S. Food and...
-
Dec 3, 2019
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it was notified via email on November 27,...